Halia Therapeutics Published in Journey of Drug Targeting
August 28, 2025
A Halia publication has been featured in the Journey of Drug Targeting: “Ofirnoflast (HT-6184): A first-in-class, orally bioavailable NEK7 inhibitor currently undergoing Phase 2 clinical evaluation.” Ofirnoflast targets inflammation at its source by preventing NLRP3 inflammasome formation and promoting its disassembly – essentially disrupting the root cause rather than just managing symptoms.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
